TY  - JOUR
TI  - Outcomes of thymoma after multimodal therapy and determinants of survival:A 16-year experience of a tertiary cancer center
AB  - Background: In this study, we aimed to evaluate the factors that contribute tosurvival outcomes in patients with thymoma treated with multimodal approaches. Methods: A total of 203 patients (105 males, 98 females; median age: 49 years;range, 17 to 77 years) with Masaoka-Koga Stage II-IV thymoma betweenJanuary 2002 and December 2018 were retrospectively analyzed. Data includingdiagnosis of myasthenia gravis, diagnosis of diabetes mellitus, disease stage,histological type of tumor, capsule invasion and surgical margin status,lymphadenectomy, adjuvant radiotherapy or chemotherapy, time from surgeryto the first day of adjuvant treatment, length of hospital stay, and overall anddisease-free survival rates were recorded. Results: Of the patients, 91 had Stage II, 67 had Stage III, and 45 had Stage IVdisease. A total of 123 patients (61%) had myasthenia gravis. Seventy-six patientsreceived adjuvant radiotherapy and 48 patients received either neoadjuvant(n=35) or adjuvant (n=25) chemotherapy. Higher disease stage, presence ofR1 resection, and treatment with chemotherapy were significant factors fordecreased disease-free survival time. Older age, higher disease stage, longerpostoperative hospital stay, chemotherapy, and disease recurrence were effectivecontributors to decreased overall survival time. Adjuvant radiotherapy had astatistically significant positive effect on overall survival only in patients withcompletely resected Stage IV disease (five-year overall survival: 94.7% vs. 79.1%,respectively; p=0.015). In the multivariate analysis, older age (hazard ratio: 4.26),higher disease stage (hazard ratio: 2.95), and longer hospitalization time (hazardratio: 3.81) were significant prognostic factors for overall survival. Patientswith local recurrence who underwent complete resection had a survival timecomparable to non-recurrent patients (p=0.753). Conclusion: For patients with thymoma, higher disease stage, age ≥50 years,longer hospitalization, and need for chemotherapy are associated with worsesurvival rates. Adjuvant chemotherapy has a positive impact on Stage IV disease.Resection of recurrent lesions has a valuable impact on survival.
AU  - Dagoglu, Nergiz
AU  - Kaytan Saglam, Esra
AU  - Aydiner, Adnan
AU  - KARA, MURAT
AU  - Ozkan, Berker
AU  - bayraktar, soley
AU  - Kaba, Erkan
AU  - karaman, sule
AU  - VATANSEVER, SEZAI
AU  - Eralp, Yesim
AU  - Ülker, Melike Güler
AU  - Toker, Alper
AU  - Aydın, Esra
AU  - Ferhatoglu, Ferhat
AU  - Yegen, Gulcin
AU  - Ak, Naziye
AU  - DİŞÇİ, RIAN
AU  - Kizir, Ahmet
DO  - 10.5606/tgkdc.dergisi.2021.20529
PY  - 2021
JO  - Türk Göğüs Kalp Damar Cerrahisi Dergisi
VL  - 29
IS  - 4
SN  - 1301-5680
SP  - 487
EP  - 495
DB  - TRDizin
UR  - http://search/yayin/detay/503212
ER  -